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Introduction
Modulation of prostaglandin metabolism is at the center of current anti-inflammatory therapies. NSAIDs and aspirin-related drugs block the activity of cyclooxygenases (Cox) and their ability to convert arachidonic acid (AA) into prostaglandin (PG) H2. PGH2 can be subsequently metabolized by terminal prostaglandin synthases to the corresponding biologically active PGs, namely, PGI2, thromboxane (Tx) A2, PGD2, PGF2α, and PGE2.
A combination of pharmacological, genetic and neutralizing antibody approaches demonstrates the importance of PGE2 in inflammation (1) (2) (3) (4) (5) (6) . In many respect, disruption of PGE2-dependent signaling in animal models of inflammation can be as effective as treatment with NSAIDs or Cox-2 inhibitors (1, 3) . The conversion of PGH2 to PGE2 may therefore represent a pivotal step in the propagation of inflammatory stimuli.
Several prostaglandin E synthases, the enzymes that convert PGH2 into PGE2, have been isolated and identified to date (7) (8) (9) (10) (11) . Five mammalian PGES isoforms have now been cloned and there are referred to as microsomal PGE synthase-1 (mPGES-1), mPGES-2, GSTM2-2, GSTM3-3, and cPGES/p23 (12) (13) (14) (15) . mPGES-1 has emerged as an important modulator of inflammation in vivo (3, 16) . mPGES-1 expression has been detected in multiple disease states both in animal models and in the clinic (17) (18) (19) and it is downregulated in vitro by classical anti-inflammatories such as dexamethasone (20, 21) . In the absence of specific mPGES -1 inhibitors, antisense and transgenic approaches have provided us with further evidence supporting a role for mPGES -1 in inflammation (3, 17, 22) . Importantly, mPGES-1-/-mice in a chronic model of inflammation, collageninduced arthritis, are mostly resistant to the development of joint arthritis (3) . The marked reduction in chronic inflammation is accompanied at the cellular level by a by guest on November 6, 2017 http://www.jbc.org/ Downloaded from greater than 95% reduction in LPS-induced PGE2 release from mPGES -1-/-peritoneal macrophages (3, 23, 24) . PGH2 serves as a common substrate for multiple prostaglandin synthases and it is therefore conceivable that the modulation of one arm of the pathway may impact substrate availability for other terminal prostaglandin synthases. For example, PGI synthase (PGIS)-deficient mice lose a significant in vivo portion of their prostacyclin production ability and this is accompanied by marked increases in systemic PGE2 and TxB2 production (25) . It is difficult to conclude, especially in view of the developmental vascular disorders observed in PGIS-deficient animals, that these results were not the reflection of complex physiological adaptation secondary to genetic compensation.
However, these studies do provide preliminary indication that in the absence of a major terminal prostanoid synthase divergence of flow to other prostanoids can occur. Our studies were designed to test this hypothesis in mPGES -1-deficient macrophages.
Macrophages are key determinants of disease processes involved in the initiation, progression and resolution of inflammation. These cells process external inflammatory cues and in turn propagate physiological responses via the release of inflammatory mediators such as PGE2, PGD2, PGI2, PGF2α, and TxA2 (26) (27) (28) . The orchestrated synthesis of these prostaglandins is an important aspect of inflammation since each of these mediators display unique and sometimes opposing cellular functions (29, 30) .
Therefore, macrophages provide a cellular model for characterizing prostaglandin metabolism. We posited that the absence of mPGES-1 expression in macrophages would be accompanied by marked 'PGH2 shunting' to prostaglandins other than PGE2. To test
Experimental Procedures
Isolation of macrophages -mPGES-1-/-and control mPGES-1+/+ mice were generated as previously described (3) . All animals used in our studies were on an inbred DBA/1lacJ genetic background. All experimentations were performed under approved protocols by the Pfizer Global Research and Development Institutional Animal Care and Use Committees. Mice were injected intraperitoneally with 0.5 ml of 10% thioglycollate media on day 0. On day 4, peritoneal lavages were then collected and processed as previously described (2) . No significant difference in the number of cells recovered from peritoneal exudates was noted between genotypes.
Cellular prostaglandin formation assays -Four different types of cellular experiments
were performed with the peritoneal macrophages isolated from mPGES-1-/-and mPGES -1+/+ mice. At the completion of each experiment, supernatants were isolated and stored at -80ºC until assayed. Media controls for each condition reflected the highest possible amount of solvent used to prepare the corresponding stimulating agent (LPS: PBS; arachidonic acid: ethanol, dazoxiben: DMSO).
For the prostaglandin measurement time course experiments, macrophages (10 5 Solid phase extraction (SPE) of the media was then performed. Acetonitrile (500 µl) containing a mixture of eicosanoid standards (1 µg each 6-keto PGF1α, TXB2, PGF2α, PGE2, PGD2 a nd 50 ng each LTD4, LTC4, LTB4 and 12-HHT, and 100 ng indomethacin was added to 250 µl of media in a 1.5 ml microcentrifuge tube. After centrifugation at 8000 x g for 2 minutes, the supernatant was transferred to a 13 x 100 mm borosilicate glass tube. After dilution with 3.5 ml 5 mM phosphoric acid in water, the supernatant was then passed through a 100 mg Bond Elut C18 column (Varian Inc., Palo Alto, CA) previously wetted with 4 ml methanol followed by 2 x 1 ml acetonitrile and 1 ml water. The tube and column were then washed with 1 ml acetonitrile / water / 
Materials -
Unless indicated otherwise, all reagents were obtained from Sigma-
Aldrich.
Statistical analysis -The values are expressed as the mean ± SEM. Group comparisons were performed by ANOVA with a Bonferroni posttest unless otherwise noted. In contrast, incubation with LPS caused a significant increase in all prostanoids measured in the supernatants isolated from wild type cells. Consistent with our time course experiments, PGE2 levels were reduced by approximately 95% in media isolated from LPS-treated mPGES-1-/-cells. Furthermore, TxB2 became the most prominent prostaglandin formed in mPGES1-/-samples. The relative order of prostaglandin abundance in -/-samples was: TxB2 > 6-keto PGF1α > PGF2α > PGD2 > PGE2. In contrast, this ranking in +/+ samples was: PGE2 > TxB2 > 6-keto PGF1α > PGF2α > PGD2. We detected an approximate 2-fold increase in levels of TxB2, 6-keto PGF1α, PGF2α and PGD2 in -/-supernatants relative to +/+ samples (Table 1) . To characterize the molecular mechanisms responsible for this altered pattern of expression, we focused on the expression of the terminal prostaglandin synthases and cyclooxygenases isoforms responsible for the formation of the most abundant prostaglandin. Pharmacological or genetic disruption of a specific terminal prostaglandin synthase can modulate the production of remaining prostaglandins. Prostanoid tissue analysis in PGIS mice revealed that PGE2 and TxB2 levels were significantly elevated in PGIS -/-animals (25) . Transfection of adenovirus encoding hematopoietic prostaglandin D synthase into fibroblasts caused an increase in PGD2 coupled with a decrease in PGE2 released into the extracellular environment (32) . In our experimental system, the thromboxane synthase inhibitor, dazoxiben, decreased TxB2 and increased PGE2 in a dose-dependent manner consistent with shunting as previously reported by other researchers (33) (34) (35) . We also noted that between baseline and the 10 µM dazoxiben-treated groups, the maximal difference in PGE2 levels was higher than that for TxB2 levels. This observation combined with a 10-fold difference in inflexion points between the PGE2 and TxB2 curves suggest that part of the increase in PGE2 production possibly reflects a mechanism other than a simple intracellular divergence of PGH2 to prostaglandin E synthase(s).
Results

Production of PGE2 in macrophages -
Induction kinetics of prostaglandin synthetic enzymes -
Interestingly, there was no increase in 6-keto PGF1α levels in wild type or knockout cells incubated with dazoxiben up to 10 µM (personal communications) suggesting that the selective blockade of a terminal prostaglandin synthase does not necessarily result in the non-discriminatory shunting of PGH2 to the remaining PG pathways.
5-Lipoxygenase-deficient mice display both decreases in LTC4 and increases in PGE2
following stimulation with Ca 2+ ionophore suggesting that at the level of arachidonic acid metabolism shunting to any eicosanoid sub-class is in principle possib le (36) . We examined the possibility that the absence of mPGES-1 expression could be accompanied by an increase in leukotriene secretion. No such evidence was obtained in our experiments. However, increases in 6-keto PGF1α, TxB2, and PGF2α were observed consistently in our diverse experimental approaches. Furthermore, significant increases in a compound that co-elutes with 12-HHT were detected possibly as a result of PGH2 breakdown which can occur through a number of enzymatic (via TxAS or P450s) or nonenzymatic pathways (37, 38) .
The coordination of prostaglandin metabolism is emerging as an important hypothesis in the regulation of inflammatory processes (30) . A recent study of human atherosclerotic plaques suggests the balance between lipocailin-type PGDS and mPGES-1 expression may be a distinguishing feature of asymptomatic and symptomatic plaques (39) . These observations suggest that the disruption of 'prostaglandin homeostatis' may thus serve as a biomarker for certain pathophysiological conditions. The balance of prostaglandins could also impact the phenotype of terminal prostaglandin synthase-deficient mice.
Administration of PGD2 causes an a nti-inflammatory effect in a rat model of carrageenan-induced pleurisy (30) . Genetic disruption of mPGES -1-dependent PGE2 production using genetically modified mice causes a significant diminution in arthritis (2,3). These observations raise the possibility that the redirection to PGD2 may be an added benefit as a result of PGH2 redirection.
During the completion of this manusc ript, Boulet and Kamei described a prostaglandin metabolic profile in mPGES-1-deficient macrophages (23, 24) . These investigators didn't detect significant increases in either 6-keto PGF1α or TxB2 levels in -/-supernatants compared to +/+ samples isolated from thioglycollate-elicited macrophages stimulated with LPS. In contrast, significant increases in both 6 -keto PGF1α and TxB2 were measured in our experimental system. Our studies were performed on an inbred DBA/1 genetic background while the other studies were completed on a mixed 129xC57/Bl6 genetic background. Multiple reports have described how differences in genetic background can impact phenotypes vis-à-vis eicosanoids-related phenotypes (40-42). To begin to understand these differences, it is interesting to note that 129 and C57/Bl6 mice, in contrast to DBA/1 or Balb/C mice, carry a mutation in the spla2 gene translating into the absence of sPLA2 IIA protein expression (41, 43) . sPLA2 IIA has been implicated in Cox-2-dependent PGE2 production and this may contribute in part to differences in prostanoid profiles (44) . Notably , significant differences in PGE2 production and levels of prostaglandin synthesizing enzymes have been previously reported between Balb/C and C57/Bl6 mice (40). It is therefore not surprising that a similar genetic deletion on two distinct genetic backgrounds can potentially result in different phenotypes.
Several questions that extend beyond the scope of this manuscript remain to be answered. Macrophages incubated with LPS were washed three times with PBS and incubated with Figure 5B 
